Dr. Leticia Rangel

Brief Biography:

Following a three-year post-doctoral fellowship at the Gerontology Research Center, NIA, NIH, under Dr. Pat J. Morin’s advising, I’ve returned to my home country Brazil, where I hold a tenure Associate Professor and Investigator position at the Federal University of Espirito Santo (UFES). I have been engaged in an independent scientific career, being the mentor, thereafter the PI, of many research projects, focusing in the elucidation of the molecular basis of ovarian, breast (especially triple-negative breast cancer), lung cancers, as well as leukemia, and in the discovery of novel strategies to treat the diseases. With this respect, my laboratory is currently investigating the antineoplastic effect of novel synthetic drugs, as well as developing monoclonal antibodies against specific targets identified through genomic and proteomic approaches.

Bibliography (h-index=10):
1. A retrospective analysis of clinicopathological and prognostic characteristics of ovarian tumors in the State of Espirito Santo, Brazil. Paes, Marcela F ; Daltoe, Renata D ; Madeira, Klesia P ; Rezende, Lucas CD ; Sirtoli, Gabriela M ; Herlinger, Alice L ; Souza, Leticia S ; Coitinho, Luciana B ; Silva, Debora ; Cerri, Murilo F ; Chiaradia, Ana Cristina N ; Carvalho, Alex A ; Silva, Ian V ; Rangel, L. B. A. Journal of Ovarian Research, v. 4, p. 14, 2011.
2. Breast and ovarian cancer treatment: Facing forward women health care. Herlinger, A. L. ; Madeira, KP ;  Daltoé, RD ;  Silva IV ; Cunegundes, M. ; Rangel, Leticia BA . In: Assoc. Prof. Dr. Öner Özdemir, Chief of Pediatrics, Div. of Allergy and Immunology, ?stanbul Göztepe Research and Training Hospital. (Org.). Cancer Treatment / Book 1. Istanbul, Turkey, 2011.
3. Evaluation of PvuII and XbaI polymorphisms in the estrogen receptor alpha gene (ESR1) in relation to  menstrual cycle timing and reproductive parameters in post-menopausal women. Silva IV, Rezende LC, Lanes SP, Souza LS, Madeira KP, Cerri MF, Paes MF, Daltoé RD, Chambô-Filho A, Guimarães MC, Graceli JB, Rangel LB. Maturitas. 2010 Dec;67(4):363-7.
4. Regulatory T cell as a target for cancer therapy. de Rezende LC, Silva IV, Rangel LB, Guimarães MC. Arch Immunol Ther Exp (Warsz). 2010 Jun;58(3):179-90.
5. Regulation and its Role in Carcinogenesis.  Cerri MF ;  Rezende, L. C. D. ;  Paes, M. F. ; 5.  Silva IV ; Rangel, L. B. A. The cotransporter NaPi-IIb: Characteristics, Applied Cancer Research (Online), v. 30, p. 197-203, 2010.
6. Prevalence of estrogen receptor alpha PvuII e XbaI polymorphisms in a population of Brazilian women.  Araújo, KL ; Madeira, KP ;  Souza SS ;  Paes, M. F. ;  Rezende, L. C. D. ; Herkenhoff, F. L. ; Rangel, L. B. A. ;
7. Silva IV . Brazilian Archives of Biology and Technology      , v. 1, p. 1-1, 2010
8. Endocrine disruption induced by organotin compounds: Impacts in thw reproductive function. Mancini, CN ; DELGADO-FILHO, V. ; RANGEL, L. B. A. ;  Silva IV ;  Pedrosa, DF ; MATSUMOTO, S. ;  Graceli, JB . Perspectivas Online (Campos dos Goitacazes), v. 4, p. 122-131, 2010
9. Fat-storing multilocular cells expressing CCR5 increase in the thymus with advancing age: potential role for  CCR5 ligands on the differentiation and migration of preadipocytes. Mello Coelho V, Bunbury A, Rangel LB, Giri B, Weeraratna A, Morin PJ, Bernier M, Taub DD. Int J Med Sci. 2009 Dec 4;7(1):1-14.
10. Growth inhibition of Staphylococcus aureus by chicken egg yolk antibodies.Guimarães MC, Amaral LG, Rangel LB, Silva IV, Matta CG, Matta MF.Arch Immunol Ther Exp (Warsz). 2009 Sep-Oct;57(5):377-82.
11. PI-PLCbeta is involved in the modulation of the proximal tubule Na+-ATPase by angiotensin II.Rangel LB, Lopes AG, Lara LS, Carvalho TL, Silva IV, Oliveira MM, Einicker-Lamas M, Vieyra A, Nogaroli L, Caruso-Neves C. Regul Pept. 2005 Apr 15;127(1-3):177-82.
12. Anomalous expression of the HLA-DR alpha and beta chains in ovarian and other cancers.Rangel LB, Agarwal R, Sherman-Baust CA, Mello-Coelho V, Pizer ES, Ji H, Taub DD, Morin PJ.Cancer Biol Ther. 2004 Oct;3(10):1021-7.
13. Preadipocyte-like cells in the aging thymus.  de Mello-Coelho V ; Rangel, L. B. A. ; Morin PJ ; Taub DD . In: Monduzzi Editore-International Proceedings Division. (Org.). (Org.). Immunology 2004- Autoimmunity, Genetic and Degenerative Disorders. : MONDUZZI EDITORE, 2004, p. 279-284.
14. Characterization of novel human ovarian cancer-specific transcripts (HOSTs) identified by serial analysis of  gene expression.Rangel LB, Sherman-Baust CA, Wernyj RP, Schwartz DR, Cho KR, Morin PJ.Oncogene. 2003 Oct 16;22(46):7225-32.
15. Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in  ovarian cystadenomas.Rangel LB, Agarwal R, D'Souza T, Pizer ES, Alò PL, Lancaster WD, Gregoire L, Schwartz DR, Cho KR, Morin PJ.Clin Cancer Res. 2003 Jul;9(7):2567-75.
16. Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin  resistance in ovarian cancer cells.Sherman-Baust CA, Weeraratna AT, Rangel LB, Pizer ES, Cho KR, Schwartz DR, Shock T, Morin PJ.Cancer Cell. 2003 Apr;3(4):377-86.
17. Angiotensin II stimulates renal proximal tubule Na(+)-ATPase activity through the activation of protein  kinase C.Rangel LB, Caruso-Neves C, Lara LS, Lopes AG.Biochim Biophys Acta. 2002 Aug 31;1564(2):310-6.  Regulation of the renal proximal tubule second sodium pump by angiotensins.Caruso-Neves C, Rangel LB, Lara LS, Lopes AG.Braz J Med Biol Res. 2001 Aug;34(8):1079-84. Review.
18. Protein kinase C-induced phosphorylation modulates the Na(+)-ATPase activity from proximal tubules.Rangel LB, Malaquias AT, Lara LS, Silva IV, De Souza AM, Lopes AG, Caruso-Neves C.Biochim Biophys Acta. 2001 May 2;1512(1):90-7.
19. Ouabain-insensitive Na(+)-ATPase activity is an effector protein for cAMP regulation in basolateral  membranes of the proximal tubule.Caruso-Neves C, Rangel LB, Vives D, Vieyra A, Coka-Guevara S, Lopes AG.Biochim Biophys Acta. 2000 Sep 29;1468(1-2):107-14.
20. Angiotensin-(1-7) modulates the ouabain-insensitive Na+-ATPase activity from basolateral membrane of the  proximal tubule.Caruso-Neves C, Lara LS, Rangel LB, Grossi AL, Lopes AG.Biochim Biophys Acta. 2000 Jul 31;1467(1):189-97.
21. Angiotensin II activates the ouabain-insensitive Na+-ATPase from renal proximal tubules through a G-protein.Rangel LB, Caruso-Neves C, Lara LS, Brasil FL, Lopes AG.Biochim Biophys Acta. 1999 Jan 12;1416(1-2):309-19.

Patents:
1. Development of a process to produce IgY antibodies anti-ovarian cancer peptide markers, 2010.
2. Specific SLC34A2/NaPi-IIb peptide sequences to the development of oncological biotechnology products for diagnosis, prognosis, and therapeutic purposes, 2011.
3. Novel antineoplastic drugs derived from pyridineylmethylamine naphthoquinones, 2011.
4. Novel aminoalcohols naphthoquinones derived from lawsone with antineoplastic activity, 2011.
5. Novel antineoplastic drugs derived from picolylamine naphthoquinones, 2011.

Academic positions:

1997-1998: Research training - The Johns Hopkins University, Baltimore, MD, USA 2000-2003 – Post-Doctoral Fellow – National Institutes of Health, NIA, MD, USA

1998-2004: Adjunct Professor - Dept. Pharmacology, Federal University of Rio de Janeiro, RJ, Brazil

2005-To the present (Tenure position) – Associated Professor – Dept. Pharmaceutical Sciences, Federal University of Espirito Santo, ES, Brazil

2005-To the present – Head of the Laboratory of Cellular and Molecular Biology of Human Cancer, Biotechnology Division, Federal University of Espirito Santo, ES, Brazil

2005-To the present – Coordinator of the Graduation in Basic and Clinical Pharmacology, Pharmaceutical Sciences, Federal University of Espirito Santo, ES, Brazil.

2005-2011 – President of Internal Committee of Biossafety, Federal University of Espirito Santo, ES, Brazil 2006-2008 – Vice-Council Member of the Superior Board of Federal University of Espirito Santo, ES, Brazil 2007-To the present – Coordinator of the Scientific Program for Undergraduation Students of the Universidade Federal do Espirito Santo, ES, Brazil

2007 – To the present – Council of the scientific board of Federal University of Espirito Santo, ES, Brazil

2007 –2011 – Council Member of the Brazilian Education Ministry for Evaluation of Universities, Colleges, and Related Institutions

2009- To the present - State Vice-Representation Member on the Northeast Biotechnology Division of the Brazilian Science and Technology Ministry

Research interests:

Cancer reasearch

Novel treatmente strategies

Immunotherapy

Cellular and Molecular basis of cancer

What I think of the idea behind WebmedCentral:

It is an innovative and actual policy to provide access to high quality science worldwide.